VX-150 (EOS-62073) is an orally bioavailable pro-drug that rapidly converts into its active moiety, which is a highly selective inhibitor of NaV1.8 relative to the other sodium channel subtypes (>400-fold).
[1] Hemme J Hijma, et, al. Pain Med. 2021 Aug 6;22(8):1814-1826.
















